SCHEMBL4193512

SCHEMBL4193512

CN(C(=O)c1cc(-c2cccc(Cl)c2)on1)c1nnc(-c2cn[nH]c(=O)c2)n1C

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 5/20 0.60
TP53 P04637 6/20 0.46
MAPK1 P28482 1/20 0.44
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
ALDH1A1 P00352 1/20 0.43
THRB P10828 2/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4199033 0.84 TP53 (0.51) TP53MAPK1NPC1RAB9AALDH1A1
SCHEMBL2924692 0.80 GRM5 (0.58) GRM5TP53MAPK1NPC1RAB9A
SCHEMBL4090451 0.78 GRM5 (0.57) GRM5TP53NPC1RAB9AALDH1A1
SCHEMBL4097309 0.78 GRM5 (0.64) GRM5TP53NPC1RAB9AALDH1A1
SCHEMBL2959324 0.75 GRM5 (1.00) GRM5TP53MAPK1NPC1RAB9A
SCHEMBL2962057 0.75 GRM5 (1.00) GRM5TP53MAPK1NPC1RAB9A
SCHEMBL2920291 0.74 GRM5 (0.68) GRM5MAPT
SCHEMBL4100056 0.72 GRM5 (0.58) GRM5TP53NPC1ALDH1A1THRB
SCHEMBL2896795 0.71 GRM5 (0.56) GRM5TP53NPC1RAB9AALDH1A1
SCHEMBL2896791 0.71 GRM5 (0.56) GRM5TP53NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090111824-A1 AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 US claimed
WO-2009054790-A1 AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 WO disclosed
WO-2009054790-A1 AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 WO disclosed
US-20090111824-A1 AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 US disclosed
US-20090111824-A1 AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 US disclosed
US-20090111824-A1 AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111824-A1 AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5 GRM5, GRIK5, GRM1 GRM5 1/4885TP53 4876/4885MAPK1 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.